Article

Cardio-facio-cutaneous syndrome: does genotype predict phenotype?

Department of Genetics at Children’s Hospital of Eastern Ontario.
American Journal of Medical Genetics Part C Seminars in Medical Genetics (Impact Factor: 3.54). 05/2011; 157(2):129-35. DOI: 10.1002/ajmg.c.30295
Source: PubMed

ABSTRACT Cardio-facio-cutaneous (CFC) syndrome is a sporadic multiple congenital anomalies/mental retardation condition principally caused by mutations in BRAF, MEK1, and MEK2. Mutations in KRAS and SHOC2 lead to a phenotype with overlapping features. In approximately 10–30% of individuals with a clinical diagnosis of CFC, a mutation in one of these causative genes is not found. Cardinal features of CFC include congenital heart defects, a characteristic facial appearance, and ectodermal abnormalities. Additional features include failure to thrive with severe feeding problems, moderate to severe intellectual disability and short stature with relative macrocephaly. First described in 1986, more than 100 affected individuals are reported. Following the discovery of the causative genes, more information has emerged on the breadth of clinical features. Little, however, has been published on genotype–phenotype correlations. This clinical study of 186 children and young adults with mutation-proven CFC syndrome is the largest reported to date. BRAF mutations are documented in 140 individuals (approximately 75%), while 46 (approximately 25%) have a mutation in MEK 1 or MEK 2. The age range is 6 months to 32 years, the oldest individual being a female from the original report [Reynolds et al. (1986); Am J Med Genet 25:413–427]. While some clinical data on 136 are in the literature, 50 are not previously published. We provide new details of the breadth of phenotype and discuss the frequency of particular features in each genotypic group. Pulmonary stenosis is the only anomaly that demonstrates a statistically significant genotype–phenotype correlation, being more common in individuals with a BRAF mutation.

1 Follower
 · 
183 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardio-facio-cutaneous syndrome (CFC) is one of the RASopathies that bears many clinical features in common with the other syndromes in this group, most notably Noonan syndrome and Costello syndrome. CFC is genetically heterogeneous and caused by gene mutations in the Ras/mitogen-activated protein kinase pathway. The major features of CFC include characteristic craniofacial dysmorphology, congenital heart disease, dermatologic abnormalities, growth retardation, and intellectual disability. It is essential that this condition be differentiated from other RASopathies, as a correct diagnosis is important for appropriate medical management and determining recurrence risk. Children and adults with CFC require multidisciplinary care from specialists, and the need for comprehensive management has been apparent to families and health care professionals caring for affected individuals. To address this need, CFC International, a nonprofit family support organization that provides a forum for information, support, and facilitation of research in basic medical and social issues affecting individuals with CFC, organized a consensus conference. Experts in multiple medical specialties provided clinical management guidelines for pediatricians and other care providers. These guidelines will assist in an accurate diagnosis of individuals with CFC, provide best practice recommendations, and facilitate long-term medical care.
    Pediatrics 09/2014; 134(4). DOI:10.1542/peds.2013-3189 · 5.30 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Rasopathies are a group of genetic disorders caused by germline mutations in multiple genes of the Extracellular signal-Regulated Kinases 1 and 2 (ERK1/2) pathway. The only previously identified missense mutation in SHOC2, a scaffold protein of the ERK1/2 pathway, led to Noonan-like syndrome with loose anagen hair. Here we report a novel mutation in SHOC2(c.519G>A; p.M173I) that leads to a Rasopathy with clinical features partially overlapping those occurring in Noonan and Cardio-Facio-Cutaneous syndromes. Studies to clarify the significance of this SHOC2 variant revealed that the mutant protein has impaired capacity to interact with protein phosphatase 1c (PP1c), leading to insufficient activation of RAF-1 kinase. This SHOC2 variant thus is unable to fully rescue ERK1/2 activity in cells depleted of endogenous SHOC2. We conclude that SHOC2 mutations can cause a spectrum of Rasopathy phenotypes in heterozygous individuals. Importantly, our work suggests that individuals with mild Rasopathy symptoms may be under-diagnosed.This article is protected by copyright. All rights reserved
    Human Mutation 09/2014; 35(11). DOI:10.1002/humu.22634 · 5.05 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Background: MEK1 mutations in melanoma can confer resistance to BRAF inhibitors although pre-existing MEK1P124 mutations do not preclude clinical responses. We sought to determine if recurrent, pre-existing MEK1P124 mutations affected clinical outcome in BRAF-inhibitor treated melanoma patients. Methods: Data from four published data sets were analyzed to determine if pre-existing MEK1P124 mutations affect radiological response or progression-free survival (PFS) in BRAFV600 mutant metastatic melanoma patients treated with vemurafenib or dabrafenib. The effects of MEK1P124 mutations on MAPK pathway activity and response to BRAF inhibition were also investigated in a series of cell models. Results: In a pooled analysis of 123 patients, the presence of a pre-treatment MEK1P124 mutation (N=12, 10%) was associated with a poorer RECIST response (33% vs 72% in MEK1P124Q/S vs MEK1P124 wild-type, p=0.018), and a shorter PFS (median 3.1 vs 4.8 months, p=0.004). Furthermore MEK1P124Q/S mutations were shown to have independent kinase activity and introduction of these mutations into a BRAF mutant melanoma cell line diminished inhibition of ERK phosphorylation by dabrafenib and enhanced clonogenic survival in the presence of dabrafenib compared to cells ectopically expressing wild-type MEK1. Consistent with these data, two BRAF mutant cell lines with endogenous MEK1P124 mutations showed intermediate sensitivity to dabrafenib, but were highly sensitive to downstream inhibition of MEK or ERK. Conclusion: Taken together our data indicate that pre-existing MEK1P124 mutations are associated with a reduced response to BRAF inhibitor therapy and identify a subset of BRAF mutant melanoma patients likely to benefit from combination therapies involving MEK or ERK inhibitors.
    Clinical Cancer Research 11/2014; 21(1). DOI:10.1158/1078-0432.CCR-14-0759 · 8.19 Impact Factor

Full-text (2 Sources)

Download
76 Downloads
Available from
May 30, 2014